Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16
Author:
Affiliation:
1. Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health England, London, UK
2. Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)
Link
http://academic.oup.com/jac/article-pdf/73/3/648/23823640/dkx438.pdf
Reference32 articles.
1. The β-lactams strike back: ceftazidime-avibactam;Zasowski;Pharmacotherapy,2015
2. New β-lactam-β-lactamase inhibitor combinations in clinical development;Shlaes;Ann NY Acad Sci,2013
3. Kinetics of avibactam inhibition against Class A, C, and D β-lactamases;Ehmann;J Biol Chem,2013
4. Structural basis for different substrate profiles of two closely related Class D β-lactamases and their inhibition by halogens;Stojanoski;Biochemistry,2015
5. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae;Livermore;Antimicrob Agents Chemother,2011
Cited by 57 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance;International Journal of Antimicrobial Agents;2024-03
2. Karbapenem dirençli Gram-negatif mikroorganizmalarda seftazidim-avibaktam duyarlılıklarının değerlendirilmesi;Journal of Medicine and Palliative Care;2023-12-31
3. In vitro, in vivo and clinical studies comparing the efficacy of ceftazidime-avibactam monotherapy with ceftazidime-avibactam-containing combination regimens against carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa isolates or infections: a scoping review;Frontiers in Medicine;2023-09-04
4. Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of Pseudomonas aeruginosa;Pharmaceuticals;2023-08-30
5. Exploring the views of infection consultants in England on a novel delinked funding model for antimicrobials: the SMASH study;JAC-Antimicrobial Resistance;2023-07-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3